SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Business productivity illustration featuring Business woman working on laptop beside giant clock, symbolizing time management, efficiency, and deadlines
Opinion
For PDUFA VIII, the most valuable incentive may be time
The FDA’s proposal to offer 50% off application fees for drugs with early-stage trials conducted in the U.S. is unlikely to achieve the intended result. What biotechs really want is speed.
September 10, 2026
 · 
5 min read
 · 
Jeremy Levin
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Merck adds 53 to New Jersey chopping block
Follow along as BioSpace tracks job cuts and restructuring initiatives.
September 9, 2026
 · 
91 min read
 · 
BioSpace Editorial Staff
Events
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and leading to debates over pricing and coverage. Learn how your company can be both patient-forward while also maximizing revenue in this unique environment.
September 9, 2026
 · 
1 min read
 · 
Jef Akst
Conceptual origami paper plane pulling business finance growth chart line flying upwards on blue sky background.
Manufacturing
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion of its portfolio.
September 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
FDA
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.
September 9, 2026
 · 
1 min read
 · 
Jef Akst
Balance. A business man maintains a balance between life and work. vector
Regulatory
Acting CBER, CDER heads become permanent as FDA works to restore stability
The decision to promote Michael Davis and Karim Mikhail from acting to permanent division heads comes as the FDA awaits the potential confirmation of Heidi Overton, President Donald Trump’s nominee for commissioner.
September 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Achieve goal concept art collage. Rising arrow chart and halftone hand pointing to center of dartboard. Business goal, achieve targets, success. Trendy modern retro vector illustration
CAR-T
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, according to BMO Capital Markets.
September 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Words IPO (Initial public offering) with the trading data on the background.
IPO
2026 IPO stock tracker: How newly public biotechs are performing
BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.
September 9, 2026
 · 
1 min read
 · 
Gabrielle Masson
Abstract retro vintage landscape with mountains and sun. Summer wavy aesthetic bakground in warm retro colors. Modern flat vector illustration with copy space for text
Venture capital
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from China’s Harbour BioMed.
September 9, 2026
 · 
2 min read
 · 
Annalee Armstrong
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS